Condition: Glycogen Storage Disease Type Ia · Sponsor: Ultragenyx Pharmaceutical Inc
The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
This description comes directly from the study's public registry record.
Patients Contact: Trial Recruitment · 1-888-756-8657 · trialrecruitment@ultragenyx.com
HCPs Contact: Medical Information · 1-888-756-8657 · medinfo@ultragenyx.com
Always discuss trial participation with your own doctor first.
| Children's Hospital of Orange County | Orange, California, United States | Recruiting |
| Children's Hospital Colorado | Denver, Colorado, United States | Recruiting |
| University of Connecticut Health Center | Hartford, Connecticut, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
| The Cleveland Clinic Foundation | Cleveland, Ohio, United States | Not Yet Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Texas Health Science Center at Houston | Houston, Texas, United States | Recruiting |
| Primary Children's Hospital | Salt Lake City, Utah, United States | Not Yet Recruiting |
| Hospital de Clinicas de Porto Alegre (HCPA) - PPDS | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| McGill University Health Center | Montreal, Quebec, Canada | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06636383